HOOKIPA Announces Changes to its Board of Directors – Resignation of Sander van Deventer

NEXT STORY
Global Veterinary Immunodiagnostics Market Insights, 2017-2028
PREV STORY
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Clover Biopharmaceuticals’ COVID-19 S-Trimer Vaccine Candidate with CpG 1018 Adjuvant
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)

author_avatar
NASDAQ Market News

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a ...

author_avatar
NASDAQ Market News

Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic ...

author_avatar
NASDAQ Market News